Posting fresh info about MS, for people with MS and their supporters

  • Hot off the ENS Press: Immunomodulatory Treatment Improves Cognitive Function in PWMS

    By Judith Moser, MD MILAN, Italy — June 26, 2009 — Patients with relapsing-remitting multiple sclerosis (RRMS) who receive glatiramer acetate (GA) or interferon (IFN) beta show [...]

    • Caroline says: 752 pts with RRMS were enrolled in 79 Italian centers and treated with either glatiramer acetate or interferon beta. After 2 years, a significant reduction in cognitive impairment was observed. At baseline, 40% of all patients showed mild cognitive impairment, and 16% showed severe cognitive impairment, which the researchers said was reduced to 30% and 11%, respectively, at 2 years.
       

Feeds

Search


Topics: current therapies
Tags: , , , , , , , .

SUPPORT / Find out More


 

TAG / CLOUD

aan, alemtuzumab, avonex, betaseron, biogen, bioms medical corp, campath, ccsvi, cis, cladribine, clarity, cognitive dysfunction, copaxone, daclizumab, dirucotide, discovery, ectrims, elan, fampridine-sr, fatigue, fda, fda fast track status, fingolimod, fty-720, genzyme, gilenia, gilenya, interferons, laquinimod, merck, merck/serono, novartis, oral ms therapies, phase iii, pml, rebif, rrms, serono, smoking, spms, stem cells, teriflunomide, teva, therapy, tysabri

ARCHIVES / PAST ARTICLES



Follow me on Twitter
Friend me on Facebook
Subscribe by Email




Bookmark and Share


Wordpress Engine. Upstart Theme. Better Project.